Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
MGMeiraGTx Holdings plc logo

MeiraGTx Holdings plc (MGTX)

NASDAQ Global Select · Currency in USD
$9.21 ▼ -0.56 (-5.73%)
At close: Oct 23, 4:00 PM ET. Market closed.
$9.45 ▲ +0.24 (+2.61%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$9.77
Open
$9.70
Day's Range
$9.08 – $9.71
52 Week Range
$6.62 – $15.35
Volume
595,502
Avg. Volume
901,814
Market Cap
$884.56M
Beta (5Y Monthly)
1.35
PE Ratio (TTM)
12.12
EPS (TTM)
$0.86
Earnings Date
Nov 12, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$21.00

Profile: MeiraGTx Holdings plc

Sector
Healthcare
Industry
Biotechnology
Full-time employees
393
CEO
Alexandria Forbes

MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease.

Earnings

Next report: Thu, Nov 12, 2026
EPS estimate -$0.46 · Revenue est. $6.95M
DateEst.Actual
Aug 13, 2026-$0.46$1.71Beat
May 14, 2026-$0.43-$0.57Miss
Mar 26, 2026-$0.60$0.19Beat
Nov 13, 2025-$0.50-$0.62Miss
Aug 14, 2025-$0.52-$0.48Beat
May 13, 2025-$0.38-$0.51Miss

Analyst view

Consensus price target
$21.00 ▲ +128.0%
Range $16.00 – $26.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on MGTX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.